Dare Bioscience Inc. (DARE)
NASDAQ (CM) NASDAQ (CM) Primary 
XBER 
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript
Daré Bioscience, Inc. ( DARE ) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns November 17, 2025 12:00 PM EST Company Participants Jennifer Kiang Sabrina Johnson - CEO, President, Principal Financial Officer, Secretary & Director Conference Call Participants Sheryl Kingsberg Jim Simon Presentation Jennifer Kiang All right. Good morning, everyone, and thanks so much for joining us today.
Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
Daré Bioscience, Inc. ( DARE ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Johnson - CEO, President, Principal Financial Officer, Secretary & Director Conference Call Participants Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the conference call hosted by Daré Bioscience to review the company's third quarter 2025 financial results and to provide a business update. This call is being recorded.
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.55 per share a year ago.
Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants MarDee J. Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - CEO, President, Principal Financial Officer, Secretary & Director Operator Welcome to the conference call hosted by Daré Bioscience Therapeutics Company's Second Quarter 2025 Financial Results and to provide a business update.
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to earnings of $1.52 per share a year ago.
Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator Welcome to the Conference Call hosted by Daré Bioscience to review the company's First Quarter 2025 Financial Results and to provide the Business Update.
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.84 per share a year ago.
Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Catherine Novack - Jones Trading Douglas Tsao - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to review the company's 2024 Financial Results and to provide a Business Update.
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.72 per share a year ago.
Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript
Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conference Call Participants Catherine Novack - JonesTrading Brian Kemp Dolliver - Brookline Capital Markets Douglas Tsao - H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the company's Third Quarter Financial Results and to provide a general business update.
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $1.08 per share a year ago.
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know
Dare Bioscience (DARE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
